About Protagonist Therapeutics
Protagonist Therapeutics is a publicly listed company based in Milpitas (United States) founded in 2001. Oral peptide therapeutics are developed for gastrointestinal diseases. Protagonist Therapeutics has raised $67 million across 10 funding rounds from investors including HHS, RA Capital and Canaan. The company has 126 employees. Its chief executive, as recorded, is Dinesh Patel. Its website protagonist-inc.com draws about 10 thousand monthly visits. Protagonist Therapeutics offers products and services including Icotrokinra and Hepcidin Mimetic. Its focus areas include Life Sciences, Gastroenterology, Drugs and Bowel Disorders. Its legal entity is Protagonist Therapeutics Inc. Its competitors include Aclaris Therapeutics, Prometheus Biosciences and Kanvas Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Protagonist Therapeutics was founded in 2001 and is headquartered in Milpitas, United States. Focus is placed on the biotechnology sector, where oral peptide therapeutics are developed for gastrointestinal conditions such as inflammatory bowel diseases and irritable bowel syndrome. The pipeline includes PTG-100, an α4β7 integrin antagonist, and IL-23 receptor antagonists for IBD treatment. Additional efforts target IL-6 as an anti-inflammatory agent and hepcidin mimetics for iron overload disorders.
- Headquarters Milpitas, United States
- Employees 126
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website protagonist-inc.com
- Social LinkedIn X
- Legal Name Protagonist Therapeutics, Inc.
- Annual Revenue$46.02 M (USD)-89.41as on Dec 31, 2025
- Net Profit-$130.15 M (USD)-147.29as on Dec 31, 2025
- EBITDA-$156.9 M (USD)-161.34as on Dec 31, 2025
- Total Equity Funding$67M (USD)
in 10 rounds
- InvestorsHHS
& 11 more
- Employee Count126
Products & Services of Protagonist Therapeutics
Protagonist Therapeutics offers a comprehensive portfolio of products and services, including Icotrokinra and Hepcidin Mimetic.
Investigational therapy targeting IL-23 receptor for inflammatory diseases
Potential treatment for blood disorders through peptide innovation
Funding Insights of Protagonist Therapeutics
Protagonist Therapeutics has successfully raised a total of $67M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $67M
- Total Rounds 10
- First Round $9M
(Sep 2006)
- Investors Count 12
All 10 funding rounds of Protagonist Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | Post-IPO | β | β | β | |
| Oct 2019 | $10M | Debt – Conventional | β | β | β |
| Sep 2018 | $1.45M | Grant | β | β | |
| Aug 2016 | $1.55M | Grant | β | β | |
| Jul 2016 | Grant | β | β | ||
| Sep 2015 | $1.56M | Grant | β | β | |
| Jul 2015 | $40M | Series C | β | Canaan | |
| Sep 2013 | $4M | Series B | β | β | |
| Jun 2013 | $14M | Series B | β | Johnson & Johnson Innovation – JJDC | |
| Sep 2006 | $9M | Series A | β | Lilly Ventures |
12 investors in total: 12 institutional.
Investors in Protagonist Therapeutics
Protagonist Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RA Capital and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
Stage-agnostic sector-agnostic VC firm investing in Australia, New Zealand and the US | starfishvc.com | Melbourne, Australia | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Early-stage life sciences investments are made globally by Inbio Ventures. | inbio-ventures.com | Moscow, Russia | ||
Research on heart, lung, blood, and sleep disorders is conducted. | nhlbi.nih.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Protagonist Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Protagonist Therapeutics
63 people are tracked at Protagonist Therapeutics (32 in leadership, 6 in board & advisors, 25 in team); the tracked headcount is 126.
| Name | Role | Group |
|---|---|---|
Dinesh Patel | CEO & President | Leadership |
Mohammad Masjedizadeh | EVP & Chief Technical Officer | Leadership |
David Y. Liu | Chief Scientific Officer, Head of Research & Development | Leadership |
Katharina Modelska | Senior Vice President, Clinical Development | Leadership |
Antonieta Sosa | VP Of Clinical Operations | Leadership |
Ashok Bhandari | EVP, Chief Drug Discovery & Preclinical Development Officer | Leadership |
Dinesh V. Patel | President & CEO | Leadership |
Ou Li | Director, Toxicology | Leadership |
Asif Ali | CFO | Leadership |
Arturo Molina | Chief Medical Officer | Leadership |
Robert Campbell | Vice President, Analytical Chemistry | Leadership |
Dinesh Tolani | Vice President, Fp&a | Leadership |
Li Z. | Director | Leadership |
Ying Liu | Sr. Director, Regulatory CMC | Leadership |
Vidhyavathi Venkataraman | Associate Director | Leadership |
Hemanth Amarchinta | Senior Director, Head Of Device And Packaging Engineering | Leadership |
Nora Boyer Ph.D., Msn, Fnp-C | Vp, Medical Affairs | Leadership |
Maura Tamony | Vice President, Financial Reporting | Leadership |
Michelle Landolfi | Vice President, Regulatory Affairs | Leadership |
Jill Kohler | Associate Director, Nonclinical Safety | Leadership |
43 more people are available in the full profile.
Complete people profiles for Protagonist Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Protagonist Therapeutics
Protagonist Therapeutics is a publicly listed company on the NASDAQ with ticker symbol PTGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Aug 2016
- Listed onNASDAQ: PTGX
- Listed entityProtagonist Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS74366E1029
- Share price$138.49 (-4.41% on the day) · 2026-10-13
- Market capitalisation$8.96B
- Price to earnings133.5
- EPS (diluted, trailing year)$1.04
- Volume (last session)1,031,829
Financials of Protagonist Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $46.0M | -$130.2M | -$156.9M |
| 2024 | $434.4M | $275.2M | $255.8M |
| 2023 | $60.0M | -$79.0M | -$90.3M |
| 2022 | $26.6M | -$127.4M | -$130.3M |
| 2021 | $27.4M | -$125.5M | -$126.2M |
Detailed financial statements for Protagonist Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Protagonist Therapeutics
4 dated milestones of Protagonist Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Protagonist Therapeutics is founded.
- Funding First funding round of $9.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Protagonist Therapeutics
Protagonist Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Prometheus Biosciences and Kanvas Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| prometheusbiosciences.com | 2016 | San Diego, United States | $130M | Drugs for gastrointestinal diseases are developed using clinical biobanks. | ||
| kanvasbio.com | 2021 | Ithaca, United States | $24.28M | Imaging solutions for microbial research and infectious diseases are provided. |
Detailed competitors of Protagonist Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Protagonist Therapeutics
The website of Protagonist Therapeutics (protagonist-inc.com) receives about 10.1K visits a month and ranks #1,632,956 among all websites worldwide, #2,198 in Biotechnology and Pharmaceuticals.
- Monthly visits10.1K
▼ 29% vs previous month
- Unique visitors5.9K
per month
- Global rank#1,632,956
among all websites
- Category rank#2,198
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.2
- Average visit25 sec
- DevicesDesktop 56% Β· Mobile 44%
Websites whose visitors overlap most with Protagonist Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| portola.com | 100% | View details | |||
| fiercebiotech.com | 71% | 858.3K | #81,022 | View details |
Top companies in Gastroenterology
3 companies that operate in the same segment as Protagonist Therapeutics (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Protagonist Therapeutics
Complete news archive for Protagonist Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Protagonist Therapeutics
Protagonist Therapeutics was founded in 2001 and raised its 1st funding round 5 years after it was founded.
Protagonist Therapeutics is headquartered in Milpitas, United States. It is registered at Milpitas, California, United States.
Dinesh Patel is the CEO of Protagonist Therapeutics, as recorded in our data.
Protagonist Therapeutics is a funded company, having raised a total of $67M across 10 funding rounds to date. The company's 1st funding round was a Series A of $9M, raised on Sep 2006.
Protagonist Therapeutics has 126 employees.
Annual revenue of Protagonist Therapeutics is $46.02M as on Dec 31, 2025.
Protagonist Therapeutics was founded in 2001 and is headquartered in Milpitas, United States. Focus is placed on the biotechnology sector, where oral peptide therapeutics are developed for gastrointestinal conditions such as inflammatory bowel diseases and irritable bowel syndrome. The pipeline includes PTG-100, an Ξ±4Ξ²7 integrin antagonist, and IL-23 receptor antagonists for IBD treatment. Additional efforts target IL-6 as an anti-inflammatory agent and hepcidin mimetics for iron overload disorders.
Protagonist Therapeutics's top competitors include Aclaris Therapeutics, Prometheus Biosciences and Kanvas Biosciences.
Protagonist Therapeutics offers Icotrokinra and Hepcidin Mimetic.
Yes, Protagonist Therapeutics is publicly traded on NASDAQ under the ticker symbol PTGX.
Protagonist Therapeutics has 12 investors. Key investors include HHS, RA Capital, Canaan, National Heart, Lung, and Blood Institute, and Adage Capital Management.
Protagonist Therapeutics operates through Protagonist Therapeutics Inc..